Archives
Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms v
2026-06-17
Network Pharmacology Uncovers SFI's Anti-Glioma Mechanisms via SRC/PI3K/AKT
Study Background and Research Question
Gliomas are among the most aggressive and treatment-resistant primary brain tumors, accounting for 30–50% of intracranial malignancies and displaying rapid proliferation, migration, and poor patient prognosis. Current therapeutic options—surgery, radiotherapy, and chemotherapy—offer limited survival benefits, with median survival typically under 17 months. Consequently, there is a critical need to identify novel molecular targets and therapeutic strategies for glioma management. Traditional Chinese medicines, such as Shenqi Fuzheng injection (SFI), have been used as adjuncts to conventional cancer therapy, but their mechanistic actions against glioma remain insufficiently defined. The reference study (Li et al., 2024) addresses this knowledge gap by probing SFI's molecular effects on glioma cell proliferation and migration, focusing on the SRC/PI3K/AKT signaling axis—a pathway frequently implicated in tumor growth and angiogenesis.Key Innovation from the Reference Study
The central innovation of this work lies in its integration of network pharmacology with experimental validation to unravel the complex, multi-targeted mechanisms of SFI in glioma biology. By systematically mapping potential SFI targets and intersecting them with glioma-associated gene networks, the study pinpoints the SRC/PI3K/AKT cascade as a pivotal mediator of SFI's anti-tumor actions. This approach not only identifies pharmacologically relevant pathways but also bridges computational predictions with in vitro and in vivo evidence.Methods and Experimental Design Insights
The investigation began with comprehensive network pharmacology analysis, including target prediction for SFI components and enrichment analysis to uncover shared molecular nodes with glioma pathophysiology. Notably, 110 SFI targets and 3,343 glioma-related targets were cross-referenced, revealing 79 overlapping candidates. Key SFI constituents—such as Codonopsis pilosula and Astragalus membranaceus—were identified for their bioactive flavonoids and saponins, compounds previously associated with anti-angiogenic and anti-metastatic properties. The study then transitioned to experimental workflows:- Cell-based assays (using U87 and T98G glioma lines) to assess proliferation (CCK-8, EdU, colony formation), migration (scratch and Transwell assays), and cell cycle distribution (flow cytometry).
- Immunofluorescence and Western blot analysis to probe EMT markers and pathway activation states.
- In vivo validation via a GL261 subcutaneous tumor model in C57BL/6 mice, with tumor growth, HE staining, and immunohistochemistry endpoints.
Core Findings and Why They Matter
The study demonstrates that SFI exerts multi-faceted anti-glioma activity:- SFI significantly inhibits proliferation and induces S-phase cell cycle arrest in U87 and T98G cells.
- Migration and invasion are suppressed, with downregulation of EMT markers—key events in metastasis and tumor aggressiveness.
- In vivo, SFI reduces tumor growth in the murine GL261 model.
- Mechanistically, suppression of the SRC/PI3K/AKT signaling pathway is identified as the major route by which SFI limits glioma progress, as supported by pathway enrichment and protein expression analyses.
Comparison with Existing Internal Articles
A related internal analysis, "Network Pharmacology Reveals SFI's Anti-Glioma Actions via SRC/PI3K/AKT", converges on similar mechanistic insights, reinforcing the critical role of the SRC/PI3K/AKT pathway in SFI's anti-glioma effects. Both works highlight the value of network pharmacology for uncovering multi-targeted intervention points in tumor biology. Further, the article "AAL-993: Advancing Tumor Angiogenesis Research with Precision" discusses the utility of selective VEGF receptor inhibitors, such as AAL-993, in dissecting angiogenic pathways in preclinical oncology models. This complements the reference study by contextualizing the importance of anti-angiogenic strategies—whether plant-derived or synthetic—for tumor growth and metastasis research.Limitations and Transferability
Despite the robust integration of computational and experimental data, several limitations should be noted:- The in vivo validation is limited to a subcutaneous mouse model, which does not fully recapitulate the complex brain microenvironment of human gliomas.
- Specific bioactive compounds responsible for the observed effects are not isolated, leaving open questions about dose-response relationships and synergistic interactions.
- Translatability to human subjects remains untested; further work with orthotopic glioma models and clinical samples is needed.
Protocol Parameters
- Cell line selection: U87, T98G, and GL261 lines are validated for glioma proliferation and migration assays.
- SFI treatment: Dose and timing should be titrated based on cell viability endpoints (e.g., CCK-8 or EdU incorporation) and pathway analysis.
- Pathway interrogation: Western blot for SRC, PI3K, AKT phosphorylation; EMT marker analysis (E-cadherin, vimentin) recommended for migration studies.
- In vivo efficacy: Subcutaneous GL261 implantation and SFI administration per reference protocol; monitor tumor volume and histology.
- For studies of angiogenesis inhibition, consider integrating validated VEGF receptor inhibitors such as AAL-993 for comparative or combinatorial protocols.